Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CALANASDAQ:SCPSNASDAQ:VAXXOTCMKTS:XSNX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCALACalithera Biosciences$0.00$0.00▼$0.05N/A-2.5616,027 shsN/ASCPSScopus BioPharma$0.00-97.0%$0.00$0.00▼$0.01$421K-0.242,185 shs221 shsVAXXVaxxinity$0.05+49,900.0%$0.01$0.00▼$0.50$6.34M-23.144,465 shs192 shsXSNXNovAccess Global$0.00$0.00$0.00▼$0.02$10K3.325,224 shs1 shs2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCALACalithera Biosciences0.00%0.00%-83.33%-83.33%-99.20%SCPSScopus BioPharma-97.00%-97.00%0.00%0.00%+50.00%VAXXVaxxinity+49,900.00%+400.00%+49,900.00%+24,900.00%-73.68%XSNXNovAccess Global0.00%0.00%-25.00%+50.00%-97.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCALACalithera Biosciences0.6069 of 5 stars0.01.00.04.50.60.00.0SCPSScopus BioPharmaN/AN/AN/AN/AN/AN/AN/AN/AVAXXVaxxinityN/AN/AN/AN/AN/AN/AN/AN/AXSNXNovAccess GlobalN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCALACalithera Biosciences 0.00N/AN/AN/ASCPSScopus BioPharma 0.00N/AN/AN/AVAXXVaxxinity 0.00N/AN/AN/AXSNXNovAccess Global 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCALACalithera BiosciencesN/AN/AN/AN/AN/AN/ASCPSScopus BioPharmaN/AN/AN/AN/AN/AN/AVAXXVaxxinityN/AN/AN/AN/A$0.11 per shareN/AXSNXNovAccess GlobalN/AN/AN/AN/A($0.58) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCALACalithera Biosciences-$39.65MN/A0.00N/AN/AN/AN/AN/AN/ASCPSScopus BioPharma-$11.61MN/A0.00∞N/AN/AN/AN/AN/AVAXXVaxxinity-$56.93M-$0.45N/A∞N/AN/AN/AN/AN/AXSNXNovAccess Global-$4.72M-$0.11N/A∞N/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCALACalithera BiosciencesN/AN/AN/AN/AN/ASCPSScopus BioPharmaN/AN/AN/AN/AN/AVAXXVaxxinityN/AN/AN/AN/AN/AXSNXNovAccess GlobalN/AN/AN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCALACalithera BiosciencesN/ASCPSScopus BioPharmaN/AVAXXVaxxinity82.95%XSNXNovAccess GlobalN/AInsider OwnershipCompanyInsider OwnershipCALACalithera Biosciences6.60%SCPSScopus BioPharma5.10%VAXXVaxxinity64.06%XSNXNovAccess Global1.44%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCALACalithera Biosciences604.87 million4.55 millionNot OptionableSCPSScopus BioPharma942.08 million39.94 millionNot OptionableVAXXVaxxinity90126.75 million45.55 millionNot OptionableXSNXNovAccess Global244.60 million43.96 millionNot OptionableXSNX, SCPS, VAXX, and CALA HeadlinesRecent News About These CompaniesGlobal wage calculator: Compare your salaryNovember 14, 2024 | money.cnn.comNovAccess Global Inc.August 28, 2024 | wsj.comNovAccess Global Inc. (XSNX)July 21, 2024 | finance.yahoo.comNovAccess Global Files Patent with Cedars-Sinai to Advance its Brain Cancer Fighting Vaccine PlatformMay 21, 2024 | finance.yahoo.comNovAccess Global Inc.: NovAccess Global Advisory on Annual Meeting of ShareholdersMay 7, 2024 | finanznachrichten.deNovAccess Global Advisory on Annual Meeting of ShareholdersMay 7, 2024 | accesswire.comNovAccess Global Announces New License to Advance its Immunotherapy PlatformApril 30, 2024 | finance.yahoo.comNovAccess Global Announces New License to Advance its Immunotherapy PlatformApril 30, 2024 | accesswire.comNovAccess Global Provides Business Updates and Announces Scheduling of Annual Meeting of ShareholdersMarch 1, 2024 | accesswire.comNovAccess Global Faces Default and Uncertain Rescue DealFebruary 7, 2024 | msn.comNovAccess Global jumps on announcing $10.7 million financingJanuary 2, 2024 | msn.comNovAccess Global Inc.: NovAccess Global Announces $10.7 Million FinancingJanuary 2, 2024 | finanznachrichten.deNovAccess Global Announces $10.7 Million FinancingJanuary 2, 2024 | finance.yahoo.comNovAccess Global Inc. to Present at the December 7th Virtual Investor SummitDecember 1, 2023 | finance.yahoo.comNovAccess Global Appoints Dr. Roscoe M. Moore, Jr. to Scientific Advisory BoardNovember 10, 2023 | finance.yahoo.comNovaccess Global Inc XSNXNovember 2, 2023 | morningstar.comBack to the Trend? Global Debt Evolution Before and After the PandemicSeptember 14, 2023 | imf.orgNovAccess Global Inc.: NovAccess Global Partners with BCN Biosciences to Expand Immunotherapy PlatformJuly 29, 2023 | finanznachrichten.deNovAccess Global Partners with BCN Biosciences to Expand Immunotherapy PlatformJuly 27, 2023 | finance.yahoo.comNovAccess Global to Participate in National Brain Tumor Society's Annual Glioblastoma Awareness DayJuly 13, 2023 | finance.yahoo.comNew MarketBeat Followers Over TimeXSNX, SCPS, VAXX, and CALA Company DescriptionsCalithera Biosciences NASDAQ:CALACalithera Biosciences, Inc. operates under a plan of liquidation that was approved in January 2023. Previously, the company was engaged in the clinical stage precision oncology biopharmaceutical business. Calithera Biosciences, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.Scopus BioPharma NASDAQ:SCPS$0.0003 -0.01 (-97.00%) As of 06/23/2025 09:46 AM EasternScopus BioPharma Inc., a clinical-stage biopharmaceutical company, focuses on developing transformational therapeutics targeting serious diseases with unmet medical needs. It offers Duet Platform, which consists of signal transducer and activator of transcription 3 (STAT3), a master immune checkpoint inhibitor and toll-like receptor 9 (TLR9), as well as includes CpG-STAT3ASO (DUET-02), CpG-STAT3siRNA (DUET-01), and CpG-STAT3decoy (DUET-03); and that develops a suite of bifunctional oligonucleotides that activate antigen-presenting cells (APCs) in the tumor microenvironment that alleviates tumor immunosuppression to jump-start T cell-mediated immune responses. The company is also developing DUET-01, as a monotherapy targeting B-cell non-Hodgkin lymphoma; DUET-02 that provides systemic delivery for treatment of solid tumors comprising prostate or kidney cancers; and DUET-03, which targets the actual STAT3 transcription factor protein. Scopus BioPharma Inc. has licensing agreements with the City of Hope, National Institutes of Health Program, and The Hebrew University of Jerusalem. The company was formerly known as Project18 Inc. and changed its name to Scopus BioPharma Inc. in December 2017. Scopus BioPharma Inc. was incorporated in 2017 and is headquartered in New York, New York.Vaxxinity NASDAQ:VAXX$0.05 +0.05 (+49,900.00%) As of 06/23/2025 09:52 AM EasternVaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology, cardiovascular diseases, and coronaviruses in the United States. Its product pipeline comprises UB-311, which is in phase 2 clinical trial that targets toxic forms of aggregated amyloid-b in the brain to fight alzheimer's disease; UB-312, which is in phase 1 clinical trial that targets toxic forms of aggregated a-synuclein in the brain to fight parkinson's disease and other synucleinopathies, such as Lewy body dementia and multiple system atrophy; and VXX-301, which is in preclinical trial, an anti-tau product candidate for various neurodegenerative conditions, including alzheimer's disease, traumatic brain injury, and chronic traumatic encephalopathy. It also develops VXX-401, which is phase 1 clinical trial that targets proprotein convertase subtilisin/kexin type 9 serine protease to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events; UB-313 that targets calcitonin gene-related peptide to fight migraines; and UB-612, neutralizes the SARS-CoV-2 virus and is in phase 3 clinical trial. The company was incorporated in 2021 and is headquartered in Merritt Island, Florida.NovAccess Global OTCMKTS:XSNX$0.0003 0.00 (0.00%) As of 06/20/2025NovAccess Global Inc., a biopharmaceutical company, develops novel immunotherapies to treat brain tumor patients in the United States. It specializes in cutting-edge research related to utilizing a patient's immune system to attack the cancer. The company was incorporated in 1997 and is headquartered in Chagrin Falls, Ohio. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Microsoft Stock Holds Steady as AI Drives Workforce Shift Top International ETFs With Dividends and Market-Beating Returns D-Wave Goes International With South Korea Partnership BigBear.ai Poised to Benefit as Palantir Dominates AI Defense Kroger Stock Confirms Buy Signal as Uptrend Gains Strength Darden Stock Set to Sizzle After Blowout Q4 and $1B Buyback Alphabet’s Comeback: The Hidden Engines Powering Google New All-Time Highs Coming for Broadcom? Wall Street Says Yes Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
